Clinical Trials in North Carolina

Showing 11241-11260 of 20,428 trials

Essure (Model ESS310) Placement Rate Study

NCT02064413

To evaluate the safety and successful placement rate of Essure Model ESS310 device and any factors that may influence the successful placement rate of this device.

Contraception

Bayer134 participantsStarted Mar 2014

Glendale, Arizona, United States • Phoenix, Arizona, United States • Colorado Springs, Colorado, United States +13 more locations

COMPLETEDPhase 241 miles

ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

NCT00325351

The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or carboplatin, is safe and helps to decrease or stop tumor growth.

Ovarian Neoplasms

Bayer45 participantsStarted Aug 2006

Tucson, Arizona, United States • Little Rock, Arkansas, United States • Bakersfield, California, United States +13 more locations

Essure (Model ESS310) Placement Rate Study

ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

Find Trials by Condition in North Carolina

OCT Pilot in Esophagus

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

Bedside Optical Retinal Assessment of Hypoxic Ischemic Encephalopathy in Infants

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease

Peer Led Asthma Self Management for Adolescents: PLASMA

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors